Drug facts

Microdosing tirzepatide

By David Chen·Editor·Reviewed September 2026

What is microdosing?¹

The term comes from patients and prescribers, not from a regulator. Cleveland Clinic describes microdosing a GLP-1 as when you intentionally take a reduced amount of the medication, and gives two reasons people do it: to make a supply last longer and therefore cost less, and out of concern about regaining weight after stopping. The same piece is direct about the evidence — there’s a lack of research on the safety of microdosing these weight loss drugs and any benefits to your health — and notes that there is not enough research to understand the effectiveness or safety of microdosing compounded GLP-1s.

The cost motive is real and worth taking seriously on its own terms. It is also the one part of this that can be settled with arithmetic rather than speculation: what a given seller actually bills over a month, at the dose you are actually on, is what our true monthly cost calculator exists to work out.

The word is not in the label²

Nowhere in the full prescribing information do the words microdose or microdosing appear. With no labeled regimen, there is also no labeled evidence, no labeled titration and no labeled safety profile for one.

No dose below 2.5 mg is an approved starting dose³

Section 2.1 states that the recommended starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks, and that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. The escalation described from there moves in 2.5 mg increments after at least 4 weeks on the current dose. There is no lower rung on that ladder. The whole schedule, including the maintenance doses and the maximum, is laid out in the approved dosing schedule and its four-week steps.

Is there a microdosing chart?⁴

No. The only dose chart in the approved label is its escalation schedule, and every step on it is a full dose given once weekly. The charts that circulate under the name “microdosing tirzepatide chart” are not drawn from the label, and none of their numbers has trial data behind it. Here is the label’s own ladder, as it is written:

If a maintenance dosage is not tolerated, the label says to consider a lower maintenance dosage, and the lowest one it names for weight is 5 mg. A missed dose is taken within 4 days or skipped, and the weekly schedule then resumes. The full schedule, with what each step is for, is on the tirzepatide dosage chart.

What sellers sell as a microdose plan⁶

The label has no microdose, but plenty of sellers sell one. The table lists 101 plans from 92 of the sellers on this site, under each seller’s own product name, with the price its page put first when we read it in September 2026. 15 of them show no price on the page itself. Some plans do not say whether the drug inside is tirzepatide; they are listed because the seller sells them as a microdose GLP-1, and the name is the seller’s.

Read it with two things in mind. A plan sold as a microdose is a product somebody named, not a lower step of the label’s schedule, because that schedule has no step below 2.5 mg. And the prices are headline figures, not comparable monthly costs: one is a first month, another the monthly rate of a prepaid plan, another a price per vial or per week, and each is printed with the period its page states. That is why the rows run A to Z rather than cheapest first. What a seller actually bills over a month is what the true monthly cost calculator works out.

What the trials actually tested⁵

Study 1 randomized 2,539 adults to a once-weekly fixed dosage of 5 mg, 10 mg, 15 mg or placebo, with an escalation period of up to 20 weeks followed by a maintenance period, and assessed weight reduction at 72 weeks. Study 2 randomized 938 adults with type 2 diabetes to 10 mg, 15 mg or placebo on the same design.

Read those arms against the question. The efficacy the approved product claims was measured at 5 mg and above, held for at least 52 weeks at a maintenance dose. Every arm was dosed once weekly, and no arm of either trial tested a dose below 2.5 mg, so there is no result to extrapolate down from. Not a negative result, an absent one.

Why this is sharper for a compounded vial³

A compounded vial has no approved schedule of its own to depart from, and its concentration is set by the pharmacy rather than standardized, so the same fraction of a vial can mean different amounts of drug from different sellers. What is and is not established about compounded preparations generally is set out in what actually differs between a compounded vial and Zepbound, and what the drug does at any dose is covered in how tirzepatide acts on GIP and GLP-1 receptors.